Clinical trials: Graves' Ophthalmopathy
Thyroid Eye Disease, Graves' Orbitopathy
Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study
The overall objective is to investigate the efficacy, tolerability, and safety of teprotumumab (a fully human monoclonal antibody [mAb] inhibitor of the insulin-like growth factor-1 receptor [IGF-1R]) administered once every 3…
- Trial name
- OPTIC (NCT03298867)
- Testing
- Teprotumumab
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 83 people
- Sponsor
- Amgen
Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease
The overall objective is to investigate the efficacy, safety and tolerability of TEPEZZA® in participants with chronic (inactive) TED (thyroid eye disease). Approximately 57 participants will be enrolled.
- Trial name
- NCT04583735
- Testing
- TEPEZZA
- Where
- 12 sites in United States
- Volunteers
- 62 people
- Sponsor
- Amgen
Thyroid Eye Disease
Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study
The overall objective is to evaluate the safety and efficacy of teprotumumab in the treatment of thyroid eye disease (TED) in participants who participated in the lead-in study HZNP-TEP-301 (NCT03298867; OPTIC) and who were…
- Trial name
- OPTIC-X (NCT03461211)
- Testing
- Teprotumumab
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 51 people
- Sponsor
- Amgen
Thyroid Eye Disease
A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease
The main goal of this study is to learn how teprotumumab will be processed in the body (Pharmacokinetics) subcutaneously and whether it is safe and tolerable after administration into adult patients with thyroid eye disease.
- Trial name
- NCT06389578
- Testing
- Teprotumumab
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Amgen
Thyroid Eye Disease, Graves' Orbitopathy
Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease
This is an expanded access protocol intended to provide access to teprotumumab for the treatment of up to 60 patients in the United States with active moderate to severe thyroid eye disease where there is no comparable or…
- Trial name
- EAP (NCT04040894)
- Testing
- Teprotumumab
- Where
- 8 sites in United States
- Sponsor
- Amgen
Thyroid Eye Disease, Graves Ophthalmopathy
Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy
The Study on efficacy of add on selenium in mild-to-moderate Graves ophthalmopathy: A Randomized Control Trial.; The study aims to evaluate the response of adding selenium in patients with Graves ophthalmopathy, focusing on…
- Trial name
- NCT06413043
- Testing
- Selenium
- Where
- India
- Volunteers
- 78 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Thyroid Eye Disease
Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease
FAPI PET has been developed as a promising approach for the evaluation of fibroinflammatory, such as in inflammatory bowel disease.
- Trial name
- NCT06359795
- Testing
- 18F-AlF-FAPI PET/CT, 99mTc-DTPA SPECT/CT
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Thyroid Eye Disease
Evaluation of the Corneal Endothelial Cell Layer by Specular Microscopy in Patients With Thyroid Eye Disease
To investigate corneal endothelial cell layer damage by specular microscopy in patients with thyroid eye disease
- Trial name
- NCT06235372
- Testing
- Specular microscopy
- Volunteers
- 30 people
- Sponsor
- Assiut University
Thyroid-Associated Ophthalmopathy
New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression
The purpose of this study is to determine whether injection of autologous fat or hyaluronic-acid injections in temporal region are effective in the treatment of temporal hollowing after lateral wall decompression in patients with…
- Trial name
- NCT02693808
- Testing
- Autologous fat injection, Hyaluronic acid injection
- Where
- Norway
- Volunteers
- 29 people
- Sponsor
- Haukeland University Hospital
Thyroid Eye Disease, Graves Ophthalmopathy
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment…
- Conditions
- Thyroid Eye Disease, Graves Ophthalmopathy, Graves Disease
- Trial name
- Teprotumumab (NCT06275373)
- Testing
- Teprotumumab Injection [Tepezza]
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Walter Reed National Military Medical Center
Thyroid Eye Disease
A Study of IBI311 in Subjects With Active Thyroid Eye Disease
This is a multicenter, randomized, double-masked, placebo-controlled Phase II/III study in subjects with active thyroid eye disease.
- Trial name
- NCT05795621
- Testing
- IBI311
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Tocilizumab, Thyroid Associated Ophthalmopathy
Efficacy and Safety of Tocilizumab for TAO
This study aims to evaluate the efficacy and safety of tocilizumab treating Thyroid Associated Ophthalmopathy.
- Trial name
- NCT06087731
- Testing
- Tocilizumab
- Where
- China
- Sponsor
- Sun Yat-sen University
Thyroid Associated Ophthalmopathy
Multi-model Image of Doxycycline in TAO
This study aims to evaluate the efficacy of doxycycline treating Thyroid Associated Ophthalmopathy by multi-modal image.
- Trial name
- NCT05112211
- Testing
- Doxycycline Hyclate
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Thyroid Eye Disease
Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease
To compare the efficacy of local injections of two different types of steroid (betamethasone suspension versus triamcinolone acetate) in management of patients with thyroid-related upper lid retraction either isolated or…
- Trial name
- NCT04976816
- Testing
- peri-levator betamethasone injection, peri-levator triamcinolone injection, peri-levator and retrobulbar betamethasone injection
- Where
- Egypt
- Volunteers
- 92 people
- Sponsor
- Assiut University
Graves Ophthalmopathy
Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' Orbitopathy
The purpose of the present interventional study is to assess the changes in the therapeutic response, ocular manifestations of Graves' orbitopathy and quality of life during the first year after orbital radiotherapy.
- Trial name
- NCT05775185
- Testing
- Orbital radiotherapy
- Where
- Bulgaria
- Volunteers
- 26 people
- Sponsor
- Medical University of Sofia
Thyroid Eye Disease
The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED)
This randomized clinical trial is designed to evaluate the effect of selected antioxidant vitamins and minerals supplement named as ASTED: 1. β- Carotene (30 mg) 2. Vit C (100 mg) 3. Vit E (Alpha-Tocopherol Acetate): 60-200 IU 4.
- Trial name
- NCT02393183
- Testing
- ASTED, Selenium
- Where
- Iran
- Sponsor
- Iran University of Medical Sciences
Thyroid Associated Ophthalmopathy
Multi-model Image of Immunosuppressive Agents in TAO
This study aims to evaluate the efficacy of immunosuppressive agents treating Thyroid Associated Ophthalmopathy by multi-model image.
- Trial name
- NCT05110040
- Testing
- immunosuppressive agent
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sun Yat-sen University
Graves Ophthalmopathy
Comparison of the Effectiveness of Two Glucocorticoid Regimens for Treatment of Graves' Orbitopathy
The goal of this interventional study is to compare the effectiveness of two different glucocorticoid regimens for treatment of active moderate-to-severe Graves' orbitopathy. The main questions it aims to answer are: 1.
- Trial name
- NCT05793359
- Testing
- Methylprednisolone
- Where
- Bulgaria
- Volunteers
- 62 people
- Sponsor
- Medical University of Sofia
Graves' Orbitopathy
A Conservative vs an Ablative Approach for Treatment of Hyperthyroidism in Patients With Graves' Orbitopathy
Graves' disease (GD) is the most frequent cause of hyperthyroidism in iodine sufficient countries and Graves' orbitopathy (GO) is its most common extrathyroidal manifestation.
- Trial name
- ABLAGO (NCT04776993)
- Testing
- Methimazole, Radioiodine or thyroidectomy
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- University of Pisa
Thyroid Associated Ophthalmopathy
A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy
Graves' orbitopathy (GO) is a disfiguring and disabling disease that profoundly impairs the quality of life of affected patients.
- Trial name
- ORGO (NCT03098225)
- Testing
- Orbital radiotherapy, Methylprednisolone
- Volunteers
- 120 people
- Sponsor
- University of Pisa